Statistics for Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Total visits
views | |
---|---|
Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study | 3 |
Total visits per month
views | |
---|---|
octubre 2024 | 0 |
noviembre 2024 | 0 |
diciembre 2024 | 0 |
enero 2025 | 0 |
febrero 2025 | 0 |
marzo 2025 | 0 |
abril 2025 | 0 |
File Visits
views | |
---|---|
10.7448IAS.20.01.21678.pdf | 2 |